{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T19:09:10Z","timestamp":1788030550212,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s13555-024-01183-3","type":"journal-article","created":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T05:01:51Z","timestamp":1718773311000},"page":"1849-1861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03349060","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03575871","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03720470","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03796676","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02201524","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02780167","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03627767","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"April W.","family":"Armstrong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Alexis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Feeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Levenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Fostvedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,19]]},"reference":[{"key":"1183_CR1","unstructured":"Pfizer Limited. Cibinqo 100 mg film-coated tablets. Summary of product characteristics. Tadworth: Pfizer Limited; 2021."},{"key":"1183_CR2","unstructured":"Pfizer Japan Inc. Cibinqo\u2122 (abrocitinib) tablets for oral use (50 mg, 100 mg, 200 mg). Tokyo: Pfizer Japan Inc.; 2021."},{"key":"1183_CR3","unstructured":"Pfizer Canada ULC. Cibinqo (abrocitinib). Product monograph. Kirkland: Pfizer Canada ULC; 2022."},{"key":"1183_CR4","unstructured":"European Medicines Agency. Cibinqo\u00ae (abrocitinib). Summary of product characteristics (SmPC). Pfizer Europe MA EEIG. Belgium: European Medicines Agency; 2024."},{"key":"1183_CR5","unstructured":"Pfizer Inc. Cibinqo (abrocitinib) tablets, for oral use. Prescribing information. New York: Pfizer Inc.; 2023."},{"issue":"10246","key":"1183_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"8","key":"1183_CR7","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1183_CR8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Tha\u00e7i D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"10","key":"1183_CR9","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, et al. Efficacy and Safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165\u201373.","journal-title":"JAMA Dermatol"},{"key":"1183_CR10","doi-asserted-by":"crossref","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693\u2013707.","DOI":"10.1007\/s40257-021-00618-3"},{"issue":"1","key":"1183_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjd.16004","volume":"179","author":"GJ Schmieder","year":"2018","unstructured":"Schmieder GJ, Draelos ZD, Pariser DM, Banfield C, Cox L, Hodge M, et al. Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study. Br J Dermatol. 2018;179(1):54\u201362.","journal-title":"Br J Dermatol"},{"key":"1183_CR12","doi-asserted-by":"crossref","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139.","DOI":"10.1001\/jamadermatol.2019.2855"},{"issue":"1","key":"1183_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1183_CR14","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1111\/bcp.15334","volume":"88","author":"J Wojciechowski","year":"2022","unstructured":"Wojciechowski J, Malhotra BK, Wang X, Fostvedt L, Valdez H, Nicholas T. Population pharmacokinetic-pharmacodynamic modelling of platelet time-courses following administration of abrocitinib. Br J Clin Pharmacol. 2022;88(8):3856\u201371.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1183_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/09546634.2016.1214671","volume":"28","author":"H Tan","year":"2017","unstructured":"Tan H, Valdez H, Griffins CE, Mrowietz U, Tallman A, Wolk R, et al. Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017;28(1):3\u20137.","journal-title":"J Dermatolog Treat"},{"key":"1183_CR16","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Boguniewicz M, Waibel J, Weisman J, Strowd L, Sun L, et al. Clinical tailoring of baricitinib 2 mg in atopic dermatitis: baseline body surface area and rapid onset of action identifies response at week 16. Dermatol Ther (Heidelb). 2022;12(1):137\u201348.","DOI":"10.1007\/s13555-021-00640-7"},{"issue":"8","key":"1183_CR17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1093\/ced\/llad129","volume":"48","author":"T Bieber","year":"2023","unstructured":"Bieber T, Thyssen JP, Irvine AD, Tsunemi Y, Chen YF, Sun L, et al. Early improvements in signs and symptoms predict clinical response to baricitinib in patients with moderate-to-severe atopic dermatitis. Clin Exp Dermatol. 2023;48(8):881\u20138.","journal-title":"Clin Exp Dermatol"},{"key":"1183_CR18","doi-asserted-by":"crossref","unstructured":"De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):adv00402.","DOI":"10.2340\/00015555-3751"},{"issue":"10290","key":"1183_CR19","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368.","journal-title":"Lancet"},{"issue":"3","key":"1183_CR20","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","volume":"13","author":"C Samuel","year":"2023","unstructured":"Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: Clinical and laboratory monitoring. Dermatol Ther (Heidelb). 2023;13(3):729\u201349.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1183_CR21","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/MOH.0000000000000170","volume":"22","author":"R Grozovsky","year":"2015","unstructured":"Grozovsky R, Giannini S, Falet H, Hoffmeister KM. Novel mechanisms of platelet clearance and thrombopoietin regulation. Curr Opin Hematol. 2015;22(5):445\u201351.","journal-title":"Curr Opin Hematol"},{"issue":"4","key":"1183_CR22","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1172\/JCI98785","volume":"129","author":"S Stivala","year":"2019","unstructured":"Stivala S, Codilupi T, Brkic S, Baerenwaldt A, Ghosh N, Hao-Shen H, et al. Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. J Clin Invest. 2019;129(4):1596\u2013611.","journal-title":"J Clin Invest"},{"issue":"4","key":"1183_CR23","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1172\/JCI127582","volume":"129","author":"DA Williams","year":"2019","unstructured":"Williams DA. Pairing JAK with MEK for improved therapeutic efficiency in myeloproliferative disorders. J Clin Invest. 2019;129(4):1519\u201321.","journal-title":"J Clin Invest"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01183-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01183-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01183-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T17:17:56Z","timestamp":1721495876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01183-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,19]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1183"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01183-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,19]]},"assertion":[{"value":"15 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"April W. Armstrong has served as a research investigator and\/or scientific advisor for Pfizer Inc., AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, EPI Health, Incyte, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Regeneron Pharmaceuticals, Sanofi Genzyme, Sun Pharma, and UCB. Andrew F. Alexis has received grants made to the institution from AbbVie, Almirall, Amgen, Arcutis, Bristol Myers Squibb, Cara Therapeutics, Castle, Dermavant, Galderma, LEO Pharma, Novartis, Valeant (Bausch Health), and Vyne; is an advisory board member or consultant for Pfizer Inc., AbbVie, Allergan, Almirall, Alphyn Biologics, Amgen, Apogee Pharmaceuticals, Arcutis, Bausch Health, Beiersdorf, Bristol Myers Squibb, Canfield, Cara Therapeutics, Castle, Cutera, Dermavant, Eli Lilly and Company, EPI Health, Galderma, Incyte, Janssen, LEO Pharma, L\u2019Or\u00e9al, Ortho Pharmaceutical, Regeneron Pharmaceuticals, Sanofi Genzyme, Swiss American, VisualDx, Vyne, and UCB; has served as a speaker for Pfizer Inc., Bristol Myers Squibb, Regeneron Pharmaceuticals, and Sanofi Genzyme; and has received royalties from Springer, Wiley-Blackwell, and Wolters Kluwer Health. Andrew Blauvelt has served as a speaker (received honoraria) for Pfizer Inc., AbbVie, Eli Lilly and Company, and UCB; served as a scientific advisor (received honoraria) for Pfizer Inc., AbbVie, Abcentra, Aclaris Therapeutics, Affibody Medical, ALIGOS Therapeutics, Almirall, Alumis Inc., Amgen, AnaptysBio, Apogee Pharmaceuticals, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient Pharmaceuticals, Evelo Biosciences, Evommune Inc., Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO Pharma, Lipidio, Microbion Biosciences, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Q32 Bio Inc., Rani, Rapt, Regeneron Pharmaceuticals, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB, Union, Ventyx, Vibliome, and Xencor; and has acted as a clinical study investigator (the institution has received clinical study funds) for Pfizer Inc., AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo Biosciences, Evommune Inc., Galderma, Incyte, Janssen, LEO Pharma, Merck, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Sun Pharma, UCB, and Ventyx. Jonathan I. Silverberg served as an investigator for Celgene, Eli Lilly and Company, F. Hoffmann-La Roche, Menlo Therapeutics, Realm Therapeutics, Regeneron Pharmaceuticals, and Sanofi Genzyme; as a consultant for Pfizer Inc., AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron Pharmaceuticals, and Sanofi Genzyme; and as a speaker for Regeneron Pharmaceuticals and Sanofi Genzyme. Fan Zhang was a former employee and shareholder of Pfizer Inc. and is currently an employee of Google LLC. Claire Feeney, Mark Levenberg, Gary Chan, and Luke Fostvedt are employees and shareholders of Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All study documents and procedures were approved by the appropriate institutional review boards\/ethics committees at each study site. The studies were conducted in compliance with the ethical principles from the Declaration of Helsinki and all International Council for Harmonisation Good Clinical Practice Guidelines. All local regulatory requirements were followed. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}